埃克替尼对血脂含量的影响:一项单中心回顾性研究
Effect of icotinib on human blood lipid contents:a single center retrospective study
陈玉冰 1于京京 1曾永联 2袁观斗 2曾智明 3何松青2
作者信息
- 1. 广西医科大学第一附属医院肝胆外科,南宁 530021
- 2. 广西医科大学第一附属医院肝胆外科,南宁 530021;区域性高发肿瘤早期防治研究教育部重点实验室(广西医科大学),南宁 530021;广西肝脏疾病免疫与代谢研究重点实验室,南宁 530021
- 3. 广西医科大学第一附属医院肿瘤科,南宁 530021
- 折叠
摘要
目的 探究酪氨酸激酶抑制剂埃克替尼对临床患者血脂的影响.方法 通过回顾性分析方法收集2015年1月至2019年7月期间,于广西医科大学第一附属医院接受埃克替尼治疗的符合纳入标准且随访信息完整的36例晚期肺癌患者病历信息,将其分为4组.观察埃克替尼治疗前后血脂水平的变化.应用配对样本t检验、方差分析、卡方检验进行数据分析.结果 埃克替尼治疗至少1个月(中位治疗时间[1个月,6个月])可显著降低患者血清总胆固醇(治疗前均值4.886 mmol/L,治疗后均值4.409 mmol/L,t=2.787,P＜0.01)、低密度脂蛋白(治疗前均值2.957 mmol/L,治疗后均值2.53 mmol/L,t=9.596,P＜0.01)和载脂蛋白B(治疗前均值1.003 mmol/L,治疗后均值0.900 mmol/L,t=2.828,P＜0.01)的含量.结论 埃克替尼可有效降低肺癌患者血脂含量,提示其可能用于非酒精性脂肪性肝病的降脂治疗.
Abstract
Objective To explore the effect of tyrosine kinase inhibitors(TKIs)that can bind to epidermal growth factor receptor(EGFR)on blood lipid in patients.Methods In this study,we retro-spectively reviewed medical record for patients with advanced lung cancer and treated with Icotinib,a first generation of EGFR-TKI,from January 2015 to July 2019.A total of 36 patients who had complete follow-up medical information were recruited and divided into four groups.The changes in blood lipid levels before and after treatment were evaluated.The paired sample Student's t test,analysis of variance(ANOVA)with Bonferroni post hoc test and Chi Square test were performed for data analysis.Results Icotinib could significantly reduce the content of serum total cholesterol(the mean before treatment was 4.886 mmol/L,the mean after treatment was 4.409 mmol/L,t=2.787,P＜0.01),low density lipoprotein(the mean before treatment was 2.957 mmol/L,the mean after treatment was 2.53 mmol/L,t=9.596,P＜0.01)and Apolipoprotein B(the mean before treatment was 1.003 mmol/L,the mean after treatment was 0.900 mmol/L,t=2.828,P＜0.01)after treatment with Icotinib for at least one month[duration of treat-ment,IQR(one month,6 months).Conclusion Icotinib can effectively reduce the lipid content of pa-tients,suggesting that it may be used in the treatment of non-alcoholic fatty liver disease.
关键词
表皮生长因子受体抑制剂/埃克替尼/高脂血症/高胆固醇血症/回顾性研究Key words
Epidermal growth factor receptor inhibitor/Icotinib/Hyperlipidaemia/Hyper-cholesteremia/Retrospective study引用本文复制引用
基金项目
广西科技基地和人才专项(桂科AA21220002)
国家重点研发计划项目(2022YFE0131600)
广西医科大学高水平创新团队及杏湖学者计划()
111计划(D17011)
出版年
2024
NETL
NSTL
万方数据